摘要
目的通过分析阿托伐他汀联合阿司匹林治疗对于中风发作期痰瘀互结型患者超敏C反应蛋白(high-sensitivity Creactive protein,hs-CRP)、P-选择素(P-selectin 140,GMP140)的影响,探讨阿托伐他汀联合阿司匹林的治疗价值。方法选取2013年5月~2013年12月南阳市中心医院治疗的175例中风发作期痰瘀互结型患者作为观察对象,根据治疗方案分为观察组89例(采取阿托伐他汀联合阿司匹林治疗),对照组86例(采取阿司匹林治疗),选取同期体检的60例健康人作为健康对照组,采用ELISA法检测各组血清hs-CRP及GMP140表达水平,比较各组hs-CRP、GMP140表达差异性。结果与健康人群比较,中风发作期痰瘀互结型患者血清hs-CRP及GMP140显著升高(P<0.05);经治疗后,2组患者血清hs-CRP及GMP140显著下降,治疗后观察组hs-CRP和GMP水平显著低于对照组(P<0.05);观察组治疗总有效率93.26%,显著高于对照组(P<0.05)。结论阿托伐他汀联合阿司匹林能够显著降低中风发作期痰瘀互结型患者hs-CRP、GMP140表达水平,是治疗痰瘀互结型中风发作期较为理想的方案之一。
Objective To analyze the atorvastatin plus aspirin for stroke onset of phlegm patients with the impact of high-sensitivity C-reactive protein(hs-CRP),GMP140( P-selectin),and to explore atorvastatin combined with aspirin therapeutic value. Methods 175 cases of stroke onset patients with phlegm and blood type were selected from May 2013 to December 2013 in Nanyang central hospital as the observation object,which divided into two groups according to the treatment plan,89 cases( taking atorvastatin combined with aspirin treatment),the control group of 86 patients(taking aspirin therapy),selected the same period of 60 healthy physical examination as a healthy control group,each group were detected by ELISA in serum hs-CRP and GMP140 expression levels were compared among groups to compare hs-CRP,GMP140 expression difference. Results Compared with healthy people,serum GMP140 and hs-CRP in the onset of stroke patients with phlegm were significantly higher( P < 0. 05); After treatment,both groups of patients,serum GMP140 and hs-CRP decreased significantly,hs-CRP and GMP140 in observation group were significantly lower than the control group(P < 0. 05); observation group total efficiency of 93. 26%,which was significantly higher(P < 0. 05). Conclusion Atorvastatin combined with aspirin can significantly reduce the onset of stroke patients with phlegm hs-CRP,GMP140 expression levels,is one of the ideal regimen for phlegm type of stroke onset.
出处
《中国生化药物杂志》
CAS
北大核心
2014年第5期69-71,共3页
Chinese Journal of Biochemical Pharmaceutics
基金
2010年国家自然科学基金(81060318)
